Gastrointestinal Stent Market

Gastrointestinal Stent Market Size and Share Forecast Outlook 2025 to 2035

The global gastrointestinal stents market is estimated to be valued at USD 530.6 million in 2025 and is projected to reach USD 889.4 million by 2035, registering a CAGR of 5.3% over the forecast period.

Quick Stats for Gastrointestinal Stent Market

• Industry Value (2025): USD 530.6 million
• Forecast Value (2035): USD 889.4 million
• Forecast CAGR (2025 to 2035): 5.3%
• Top Segments Driving Growth:
  • Biliary Stents: (~46.8%)
• Key Growth Region: North America and Europe
• Top Key Players: Medtronic Plc, Boston Scientific Corporation, Cook Medical, Conmed corporation, W. L. Gore & Associates, Inc., Olympus Corporation, Hobbs Medical, Inc., Merit Medical Systems, BVM Medical Ltd, Becton, Dickinson and Company

Metric	Value
Market Size in 2025	USD 530.6 Million
Projected Market Size in 2035	USD 889.4 Million
CAGR (2025 to 2035)	5.3%

The market growth is driven by the rising prevalence of gastrointestinal cancers, benign strictures, and biliary obstructions that require minimally invasive palliative interventions. Healthcare providers have increasingly adopted stent placement procedures to relieve obstructions, improve patient quality of life, and reduce hospital stay durations compared to open surgical approaches.

Advances in stent design have enhanced radial force, flexibility, and biocompatibility, supporting wider clinical acceptance. Regulatory approvals of next-generation covered and uncovered stents have accelerated product launches and broadened procedural applications. Hospitals and specialty clinics have prioritized investments in endoscopy units and physician training to support higher procedure volumes and improve outcomes.

Analyzing Gastrointestinal Stent Market by Top Investment Segments

Biliary Stents Lead the Market with Widespread Use in Managing Malignant and Benign Biliary Obstructions

Biliary Stents dominate the market with a revenue share of 46.8% has been attributed to biliary stents, reflecting their established role in treating obstructive jaundice and maintaining bile duct patency. Utilization has been supported by the high incidence of pancreatic and biliary tract malignancies, where palliative drainage remains a primary therapeutic goal.

Advances in stent design have resulted in improved patency rates, ease of deployment, and compatibility with endoscopic retrograde cholangiopancreatography procedures. Hospitals and specialized centers have prioritized biliary stenting as a first-line approach to avoid invasive surgical bypass, contributing to higher procedural volumes. Reimbursement policies in major healthcare markets have supported the use of biliary stents as a standard intervention, strengthening their leadership within the product segment.

Self-Expanding Metal Stents Dominate the Market with Preference for Durable, High-Patency Devices in Complex Obstructions

Self-Expanding Metal Stents holds a revenue share of 32.7% has been attributed to self-expanding metal stents, reflecting their preferred status in managing malignant and complex gastrointestinal obstructions. Utilization has been driven by the superior radial force, conformability, and longer patency offered by metal stents compared to plastic alternatives.

Advances in alloy composition and mesh design have enhanced deployment accuracy and reduced migration risk. Hospitals and specialty endoscopy units have adopted self-expanding metal stents to improve patient outcomes and decrease the need for frequent reinterventions. Manufacturers have invested in innovations such as anti-reflux valves and customized sizing options to address diverse anatomical requirements.

Hospitals and Clinics Anchor the Market with Integrated Endoscopy Services and High Procedural Volumes

Hospitals and clinics have accounted for 67.8% of market revenue, driven by their central role in performing gastrointestinal stenting procedures across oncology and gastroenterology practices. Adoption has been reinforced by the availability of advanced imaging modalities, trained endoscopists, and multidisciplinary care teams required to manage complex obstructive diseases.

Investment in endoscopy suite modernization and expanded capacity has supported higher procedure volumes and reduced patient wait times. Reimbursement frameworks have favored in-hospital procedures to ensure close monitoring and immediate management of complications. Clinical guidelines have endorsed stenting as a standard of care in malignant obstruction, further supporting hospital-based adoption.

Challenges and Opportunities

Challenges

High Procedure Costs, Risk of Complications, and Regulatory Hurdles

The market is witnessing a notable growth rate, nevertheless the high cost of GI stent placement and post-operative care and visit to specialty centres is a matter of concern for the market as affordability is an issue for developing healthcare markets. Additionally, risks including stent migration, occlusion and perforation fester against the broader adoption of stent therapy, leaving room for innovation in the design and materials of stents.

Moreover, stringent regulatory clearances from various organizations such as the FDA, EMA, and regional health agencies mandate comprehensive clinical trials, as well as adherence to changing medical device standards, prolonging the time to market for novel stent technologies.

Opportunities

Increase in Minimally Invasive Procedures, Increasing Geriatric Population, and Biodegradable Stent Innovations

The market is growing despite challenges owing to the rising preference for minimally invasive procedures that require shorter recovery time as well as lower hospital stays. The growth of the advanced stenting system is driven by the increasing geriatric population, the rising prevalence of gastrointestinal cancers, the rising number of strictures, and gastrointestinal obstruction.

Biodegradable and drug-eluting stents are further promising the options to mitigate risks of permanent metallic stents and the long-term concerns with permanent metallic stents. The market potential is further boosted by innovations in smart stent technologies powered by artificial intelligence real-time monitoring.

Country-Wise Outlook

United States

The growing adoption of self-expandable as well as drug-eluting stents due to the high market penetration of prominent medical device manufacturers as well as favorable reimbursement policies is positively influencing the market. Moreover, fast advancements in bioresorbable stents and smart diagnostic implants are driving market innovation.

In addition, the rising preference for outpatient endoscopic treatment and increasing establishment of ambulatory surgical centre is further supporting the market growth.

Country	CAGR (2025 to 2035)
USA	5.4%

United Kingdom

Market growth in the UK is stable due to investment from the government in cancer treatment, increasing adoption for endoscopic surgery, and technological advancements in GI stents. With the National Health Service (NHS) programs for early cancer detection and minimal invasiveness, self-expanding stents are more and more applied for oesophageal and colorectal obstructions.

Meanwhile,the increasing adoption of AI-assisted diagnostics and robotic-assisted endoscopic services is generating a plethora of opportunities for next-generation GI stents.

Country	CAGR (2025 to 2035)
UK	5.2%

European Union

Strict medical device regulations, increasing demand for minimally invasive treatment options, and rising cases of gastrointestinal cancer are key factors driving the growth of the gastrointestinal stent market in Europe. Countries such as Germany, France, and Italy are at the forefront of advanced endoscopic procedures, increasing the need for high-performance, drug-coated stents.

The European Union Medical Devices Regulation (EU MDR) is forcing the hand of manufacturers to create stents that are safer, more durable, and biocompatible. Furthermore, introduction of biodegradable stents and smart monitoring devices is creating new opportunities for market growth.

Country	CAGR (2025 to 2035)
EU	5.3%

Japan

The Japan gastrointestinal stent market is still growing driven by the fast-growing elderly population, rising adoption of high-tech endoscopic treatment and high inclination towards early cancer detection. All these factors contribute to the growing development of sensor-embedded and biodegradable stents on account of the country’s advanced medical infrastructure and AI-integrated diagnostic solutions. Moreover, the high incidence of stomach and colonic malignancy is augmenting the demand for self-expanding metallic and polymer-coated stents. Patients are also benefiting from advances in nanotechnology-based stent coatings.

Country	CAGR (2025 to 2035)
Japan	5.3%

South Korea

The gastrointestinal stent market is expected to be driven by factors such as increasing investments pertaining to medical device innovation, rising preference towards endoscopic treatments for a broad spectrum of gastrointestinal diseases, and increasing incidence rate of cancers in South Korea.

The demand for next-generation GI stents in the country is mainly supported by strong healthcare infrastructure in the country, increasing penetration of AI-based medical technologies, and government-supported cancer screening programs. Furthermore, the partnerships between medical device companies and biotech companies are tackling chronic gastrointestinal diseases and developing bioresorbable and drug-eluting stents.

Country	CAGR (2025 to 2035)
South Korea	5.4%

Competitive Outlook

Competition in the gastrointestinal stent market has been shaped by companies focusing on product innovation, regulatory expansion, and clinician education to strengthen market presence. Leading manufacturers have launched next-generation covered stents, biodegradable platforms, and customized delivery systems designed to improve safety and efficacy.

Strategic collaborations with hospitals and academic centers have been pursued to conduct clinical trials and validate performance in diverse patient populations. Investments have been directed toward expanding global distribution networks and providing procedural training to support adoption in emerging regions. These initiatives are anticipated to drive differentiation and sustain competitive intensity as demand for advanced gastrointestinal stenting continues to rise.

Key Development:

• In 2024, Olympus Corporation announced the closing of the acquisition of Taewoong Medical Co., Ltd, a Korea-based manufacturer of gastrointestinal (GI) metallic stent.
• In 2024, the National Health Insurance Administration (NHIA) has included biliary stent placement for patients with malignant biliary obstruction in the payment package starting this June, 2024. The new measure is expected to benefit over 4,000 cancer patients each year, utilizing approximately 170 million points from the NHI budget.

Companies

• Medtronic Plc
• Boston Scientific Corporation
• Cook Medical
• ELLA-CS, s.r.o.
• Conmed corporation
• W. L. Gore & Associates, Inc.
• Olympus Corporation
• Hobbs Medical, Inc.
• Merit Medical Systems
• BVM Medical Ltd
• Becton, Dickinson and Company

Key Segments

By Product:

• Biliary Stents
• Duodenal Stents
• Colonic Stents
• Pancreatic Stents
• Esophageal Stents

By Material:

• Self-Expanding Metal Stents
• Plastic Stents

By Application:

• Biliary Diseases
• Irritable Bowel Syndrome
• Gastrointestinal Cancers
• Colorectal Cancer
• Stomach Cancer
• Esophageal Cancer
• Pancreatic Cancer

By End User:

• Hospitals and Clinics
• Ambulatory Surgical Centers

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• The Middle East and Africa (MEA)